Specialty Pharmacy Continuing Education

Specialty Pharmacy Times is pleased to provide a list of continuing pharmacy education (CPE) activities from the Pharmacy Times Office of Continuing Professional Education (PTOCPE) as a resource for specialty pharmacists. PTOCPE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of CPE.

These CPE-accredited activities are free of charge and focus on chronic diseases relevant to specialty pharmacy. They are available at www.pharmacytimes.org and you will automatically be redirected to this Website once you select an activity.

ALS is a progressive disease in which the motor neurons eventually die, and mortality is usually the result of respiratory failure. Currently, there is no cure for ALS. However, in the last decade advances have been made in both discovery and research that are promising. As new therapies enter the forefront of ALS care, a multitude of healthcare professionals will need to understand more about the disease state, therapy, and their role within ALS care. This activity will explain the impact of amyotrophic lateral sclerosis (ALS) and the value of early diagnosis; examine recent ALS therapy advances, including the efficacy and mechanism of action of new agents; analyze the implications of ALS therapy in the managed care setting; and distinguish the need for integrations among physicians and specialty and managed care pharmacists in the coordination of care for patients with ALS.

Over the past decade, the number of therapeutic options for CLL have increased. As our knowledge of the biology of CLL has grown, targeted therapies directed at B-cell receptor signaling and other aberrant B-cell processes have emerged. Therapy has become more patient-specific through an understanding of risk factors and prognostic indicators. Chemoimmunotherapy remains the mainstay of treatment of CLL but newer targeted therapies such as ibrutinib, idelalisib, and venetoclax are becoming standards of care, as demonstrated by the adoption of targeted therapies into national guidelines. In addition to clinical efficacy, adverse event profiles must be considered. This activity will discuss new CLL treatment options and their place in therapy.

This continuing education activity will enable pharmacists to become more knowledgeable about current and emerging pharmacologic treatment options in rheumatoid arthritis. Requirements necessary for approval of a biosimilar agent will be explained. Pharmacists will learn that to minimize treatment failure, maximize adherence, and optimize outcomes, patient communication is vital in the management of rheumatoid arthritis

This activity will serve as a lesson in Parkinson’s Disease focusing on the disease state, Parkinson’s associated psychosis, the newest treatment options, and best practices to promote improved patient outcomes. Discussions will be held around clinical features and risk factors of Parkinson’s disease Psychosis (PDP), pharmacology, safety, and efficacy of treat options, as well as management strategies for patients with PDP.

Multiple sclerosis is a chronic inflammatory disease, which affects between 400,000 and 570,000 people in the US. Specialty pharmacists are in a unique position to manage patients with MS, and it is important they receive the education needed to better detect drug-related problems and resolve any negative outcomes associated with medication. Specialty pharmacists can also help patients with MS adhere to their medication regimen.

Atopic dermatitis is a common skin disorder observed in children and adults. As pharmacists are easily accessible health care professionals, many patients may first visit a pharmacy to seek advice and/or treatment of this skin condition. It is crucial for pharmacists to be able to recognize and assess this disorder, as well as recommend the appropriate self-care options or refer the patient to an appropriate provider. Additionally, pharmacists must be knowledgeable of commonly used and emerging therapeutic agents, plus be able to advise patients regarding the proper use of prescribed topical and systemic medications.

Recent advances in the treatment of infection with hepatitis C virus (HCV) have brought an influx of agents with favorable efficacy and tolerability that have altered the clinical progression of HCV, even in patients with complications. Interferon-free, all-oral regimens optimize patient adherence and improve outcomes for patients. The resulting spike in short-term spending by payers and patients is postulated to fall substantially over the next 10 years as cure rates increase, dosing regimens shorten periods of treatment duration, and generic substitutions are introduced. However, the myriad of treatment options, along with the nature of the infection and potential comorbidities, make it imperative that the entire health care team (physicians, pharmacists, and providers) remains up-to-date on emerging therapeutics, their mechanisms of action, clinical and real-world data, and evolving treatment guidelines. Education is vital for managed care clinicians and providers to ensure that patients receive the most effective and individualized treatment plans possible for chronic HCV.

Becoming a national epidemic, currently there are over 26 million Americans and about 285 million individuals worldwide who suffer from type 1 diabetes (T1D) or type 2 diabetes (T2D). Of the total population of patients with diabetes worldwide, about 35% have diabetic retinopathy, and about 12% of all new cases of blindness each year are secondary to diabetic retinopathy. Diabetic macular edema (DME) can occur in any stage of proliferative diabetic retinopathy (PDR) or non-proliferative diabetic retinopathy (NPDR). Therefore, this activity will demonstrate the risk factors, pathophysiology, and etiology of DME, as well as examine the mechanism of action and safety and efficacy profile of the different treatment classes and individual agents available for the management of the condition. The role of the pharmacist in educating patients on the importance of eye examinations and early detection in preventing loss of vision will also be examined.

This CE activity will examine the challenges that clinicians will face in adopting biosimilars, as well as explain the development and approval process for these new agents. It will also identify how biosimilars differ from generics. Additionally, with the first FDA approval of a biosimilar in 2015, and a FDA advisory panel recommended approval of a second for 2016, the introduction of biosimilars into the US market brings with it numerous questions for providers, patients, and payers. Therefore, a discussion on how formulary and clinical adoption of biosimilar agents will impact managed care will also be included.

This CE activity identifies common comorbidities, with a focus on signs and symptoms of psoriasis and psoriatic arthritis and the need for increased recognition. The activity will discuss the efficacy and safety of current and emerging treatments for psoriasis and psoriatic arthritis, characterize the major barriers to optimal adherence to treatments, and describe the role of the specialty pharmacist in overcoming these issues.

This CE activity explains the pathophysiology, clinical presentation, and economic burden associated with multiple sclerosis (MS). The activity will illustrate current treatment options and emerging therapies in MS. Participants will analyze potential opportunities for the specialty pharmacist to provide disease awareness through effective patient education to optimize adherence and improve outcomes.

This CE activity is a review of current and emerging therapies used to slow disease progression in patients with RA with a focus on individual patient needs. Discussion includes synthetic (traditional) DMARDs, biologic DMARDS, anti-TNF inhibitors, and non-anti-TNF inhibitors as well as emerging therapies. Nonadherence, disease assessment tools, adverse events, and resolving complications are also reviewed.

Chronic hepatitis C virus (HCV) infection is highly prevalent in the United States and estimated to impact up to 3.2 million Americans. Unfortunately, due to its insidious and largely asymptomatic nature, up to 85% of infected individuals may be unaware of their HCV infection. This continuing education program is designed to provide a clinical overview of HCV infection, summarize current screening guidelines and risk factors, identify appropriate treatment regimens and counseling strategies for patients with chronic HCV infection, and to review the safety and efficacy of current and pipeline treatment options for the disease.

Psoriasis is a chronic autoimmune skin disease that significantly reduces overall health and well being. Pharmacists practicing in the community and in specialty pharmacy settings can help patients optimize the benefit received from treatment regimens. The second of two cases, this case study will examine the use of disease-modifying antirheumatic drugs (DMARDs) and biologics for the management of psoriasis and psoriatic arthritis and review the associated safety concerns.

Psoriasis is a chronic autoimmune skin disease that can significantly impact the overall health and well being of the patient. Pharmacists practicing in the community and specialty pharmacies are able to help patients optimize treatment regimens for this condition. The first of two cases, this case study will examine topical treatment strategies and phototherapy for patients with psoriasis and discuss the role of pharmacists in the appropriate management of the disease.

This activity is intended to examine how these psoriasis comorbidities are identified and managed. The signs and symptoms of psoriasis will be reviewed. The impact of Psoriatic Arthritis, its prevalence, disease characteristics and screening tools will be illustrated. The efficacy and safety of current and emerging treatments for psoriasis and psoriatic arthritis will be summarizied.

Specialty pharmacists work as part of a multidisciplinary team to provide a number of services to manage drug utilization, including monitoring patients for compliance, offering product training to providers and patients, managing pharmacokinetics and drug interactions, and reducing the potential for serious adverse events. This CE activity will focus on current management of RA, with a review of comparative effectiveness data on the various therapies, as well as their role in the management of RA.

With the introduction of new medications and the growing number of biologics, the treatment of multiple sclerosis (MS) has become more complex changing the roles of specialty pharmacies and pharmacists. This accredited activity will focus on the specialty pharmacist's role in improving medication management in the treatment of MS.

Considering the emergence of complex testing and increased numbers of therapeutic agents for non-small cell lung cancer (NSCLC), it is imperative for specialty pharmacists to remain abreast with advances in diagnosis and treatment to optimize therapy selection and improve patient adherence. This CE activity will focus on strategies for specialty pharmacists to optimize their role in the management of NSCLC.

This CE activity is intended to examine how these psoriasis comorbidities are identified and managed. The signs and symptoms of psoriasis will be reviewed. The impact of Psoriatic Arthritis, its prevalence, disease characteristics and screening tools will be illustrated. The efficacy and safety of current and emerging treatments for psoriasis and psoriatic arthritis will be summarized.

This CE activity is intended to explore new and future therapeutics for the management of prostate cancer, and specifically castration-resistant prostate cancer (CRPC). It also examines the role of specialty pharmacists in optimizing outcomes in patients with CRPC.

This CE activity examines the epidemiology, pathophysiology, and clinical progression of multiple sclerosis (MS) while evaluating current and emerging therapeutic strategies for slowing disease progression. It also discusses the role of specialty pharmacists in maximizing outcomes in patients with MS.

This webinar will examine the latest trends in the epidemiology and pathophysiology of HIV, discuss antiretroviral regimens for treatment, experienced patients, and explore new and emerging antiretroviral regimens and therapeutic strategies.

This CE activity is intended to explore prevalence and diagnosis of COPD and to review current guideline recommendations on management of this chronic airway disease. The discussion will also center on proper selection and use of currently available medication devices and the pharmacists' role in optimizing management of COPD

This continuing education activity reviews current treatment recommendations for chronic obstructive pulmonary disease and examines currently available medication devices.

This continuing education activity examines 8 of the new drugs approved in 2012, including treatments for multiple myeloma, actinic keratosis, epilepsy, multiple sclerosis, and basal cell carcinoma.

This case study provides a practice-focused discussion of a patient presenting 3 months post living donor transplant. The activity is intended to examine clinical issues and common co-morbidities facing patients with kidney transplant. Also included is a discussion on the role and differentiating characteristics of currently available immunosuppressive regimens and the pharmacist's role in counseling patients on associated adverse effects and drug interactions.

This case study provides a practice-focused discussion on management of a patient presenting for cadaveric renal transplantation as a result of end-stage renal disease secondary to interstitial nephritis. The activity is intended to examine clinical issues and common co-morbidities facing patients with kidney transplant, as well as to discuss the role and differentiating characteristics of currently available immunosuppressive regimens.

This continuing education activity examines the unique clinical issues facing kidney transplant patients, with a focus on the mechanisms of action, adverse effects, and interaction profiles of immunosuppressive therapies.

Most Popular

Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.